Sugiura Atsushi, Tanaka Tetsu, Kavsur Refik, Öztürk Can, Vogelhuber Johanna, Silaschi Miriam, Weber Marcel, Zimmer Sebastian, Nickenig Georg
Department of Internal Medicine II, Heart Center Bonn, Bonn, Germany.
Department of Internal Medicine II, Heart Center Bonn, Bonn, Germany.
J Cardiol. 2025 Mar 17. doi: 10.1016/j.jjcc.2025.03.009.
Tricuspid regurgitation (TR) is a prevalent cardiovascular disease necessitating innovative treatments. Assessing comorbidities, such as right ventricular dysfunction, is pivotal for the therapeutic strategy. Preprocedural echocardiographic assessments are crucial for achieving optimal TR reduction. Transcatheter interventions have emerged as less invasive therapies. Tricuspid transcatheter edge-to-edge repair is the predominant technology, proven safe and effective in reducing TR. Additionally, transcatheter tricuspid valve replacement and direct annuloplasty technologies have been developed and recognized as attractive alternatives, each with unique advantages. This review discusses the innovation, current landscape, and future perspective of transcatheter tricuspid valve interventions for treating TR.
三尖瓣反流（TR）是一种常见的心血管疾病，需要创新的治疗方法。评估合并症，如右心室功能障碍，对于治疗策略至关重要。术前超声心动图评估对于实现最佳的三尖瓣反流减少至关重要。经导管介入治疗已成为侵入性较小的治疗方法。经导管三尖瓣缘对缘修复是主要技术，已被证明在减少三尖瓣反流方面安全有效。此外，经导管三尖瓣置换术和直接瓣环成形术技术也已得到发展，并被认为是有吸引力的替代方法，每种方法都有其独特的优势。本文综述了经导管三尖瓣介入治疗TR的创新、现状和未来展望。
